ANRO
Price
$3.14
Change
+$0.02 (+0.64%)
Updated
Aug 15 closing price
Capitalization
85.01M
CGON
Price
$25.70
Change
-$0.26 (-1.00%)
Updated
Aug 15 closing price
Capitalization
1.96B
Interact to see
Advertisement

ANRO vs CGON

Header iconANRO vs CGON Comparison
Open Charts ANRO vs CGONBanner chart's image
Alto Neuroscience
Price$3.14
Change+$0.02 (+0.64%)
Volume$58.68K
Capitalization85.01M
CG Oncology
Price$25.70
Change-$0.26 (-1.00%)
Volume$588.84K
Capitalization1.96B
ANRO vs CGON Comparison Chart in %
Loading...
ANRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANRO vs. CGON commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a Hold and CGON is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (ANRO: $3.14 vs. CGON: $25.70)
Brand notoriety: ANRO and CGON are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 26% vs. CGON: 45%
Market capitalization -- ANRO: $85.01M vs. CGON: $1.96B
ANRO [@Biotechnology] is valued at $85.01M. CGON’s [@Biotechnology] market capitalization is $1.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 1 FA rating(s) are green whileCGON’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 1 green, 4 red.
  • CGON’s FA Score: 0 green, 5 red.
According to our system of comparison, ANRO is a better buy in the long-term than CGON.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 4 TA indicator(s) are bullish while CGON’s TA Score has 3 bullish TA indicator(s).

  • ANRO’s TA Score: 4 bullish, 5 bearish.
  • CGON’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ANRO is a better buy in the short-term than CGON.

Price Growth

ANRO (@Biotechnology) experienced а +2.28% price change this week, while CGON (@Biotechnology) price change was +3.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGON($1.96B) has a higher market cap than ANRO($85M). CGON YTD gains are higher at: -10.391 vs. ANRO (-25.768). ANRO has higher annual earnings (EBITDA): -60.98M vs. CGON (-134.35M). CGON has more cash in the bank: 688M vs. ANRO (161M). CGON has less debt than ANRO: CGON (1.04M) vs ANRO (26.4M). CGON has higher revenues than ANRO: CGON (662K) vs ANRO (0).
ANROCGONANRO / CGON
Capitalization85M1.96B4%
EBITDA-60.98M-134.35M45%
Gain YTD-25.768-10.391248%
P/E RatioN/AN/A-
Revenue0662K-
Total Cash161M688M23%
Total Debt26.4M1.04M2,548%
TECHNICAL ANALYSIS
Technical Analysis
ANROCGON
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 11 days ago
88%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ANRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSSAX31.61N/A
N/A
Emerald Finance & Bking Innovt Fd A
FDIKX50.73N/A
N/A
Fidelity Diversified International K
MIEZX16.22N/A
N/A
MM S&P 500® Index R5
JUSOX26.17N/A
N/A
JHancock New Opportunities R4
TASHX15.51N/A
N/A
Transamerica Multi-Asset Income A

ANRO and

Correlation & Price change

A.I.dvisor tells us that ANRO and NUVL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANRO and NUVL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
+0.64%
NUVL - ANRO
30%
Poorly correlated
-0.99%
XTLB - ANRO
27%
Poorly correlated
-0.70%
NTLA - ANRO
24%
Poorly correlated
+0.83%
CRSP - ANRO
24%
Poorly correlated
+1.55%
CGON - ANRO
23%
Poorly correlated
-1.00%
More

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
-1.00%
IDYA - CGON
61%
Loosely correlated
-0.16%
SYRE - CGON
61%
Loosely correlated
+0.53%
ACLX - CGON
57%
Loosely correlated
+3.09%
NUVL - CGON
55%
Loosely correlated
-0.99%
KYMR - CGON
55%
Loosely correlated
+2.60%
More